HK1216429A1 - 用於純化芳基硫酸酯酶 的方法 - Google Patents

用於純化芳基硫酸酯酶 的方法

Info

Publication number
HK1216429A1
HK1216429A1 HK16104341.0A HK16104341A HK1216429A1 HK 1216429 A1 HK1216429 A1 HK 1216429A1 HK 16104341 A HK16104341 A HK 16104341A HK 1216429 A1 HK1216429 A1 HK 1216429A1
Authority
HK
Hong Kong
Prior art keywords
rylsulfatase
purification
methods
Prior art date
Application number
HK16104341.0A
Other languages
English (en)
Inventor
Nichols Dave
Quinones-Garcia Igor
Lin Cheang Bee
Huei Jang Mei
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of HK1216429A1 publication Critical patent/HK1216429A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16104341.0A 2013-01-09 2016-04-15 用於純化芳基硫酸酯酶 的方法 HK1216429A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361750693P 2013-01-09 2013-01-09
PCT/US2014/010856 WO2014110246A1 (en) 2013-01-09 2014-01-09 Methods for purification of arylsulfatase a

Publications (1)

Publication Number Publication Date
HK1216429A1 true HK1216429A1 (zh) 2016-11-11

Family

ID=50002885

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16102496.7A HK1214622A1 (zh) 2013-01-09 2016-03-04 含用於純化芳基硫酸酯酶 的方法
HK16104341.0A HK1216429A1 (zh) 2013-01-09 2016-04-15 用於純化芳基硫酸酯酶 的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16102496.7A HK1214622A1 (zh) 2013-01-09 2016-03-04 含用於純化芳基硫酸酯酶 的方法

Country Status (12)

Country Link
US (2) US11407984B2 (zh)
EP (1) EP2943568B1 (zh)
JP (5) JP6427502B2 (zh)
CN (2) CN104903442A (zh)
AU (3) AU2014205441B2 (zh)
BR (1) BR112015015948B1 (zh)
CA (1) CA2896979C (zh)
EA (1) EA030551B1 (zh)
ES (1) ES2768261T3 (zh)
HK (2) HK1214622A1 (zh)
MX (2) MX2015008875A (zh)
WO (1) WO2014110246A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013009686A2 (en) * 2011-07-08 2013-01-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a
JP6783767B2 (ja) * 2014-12-22 2020-11-11 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 組換えタンパク質を精製する方法
CA2995385A1 (en) * 2015-08-20 2017-02-23 Genentech, Inc. Purification of fkpa and uses thereof for producing recombinant polypeptides
WO2017160636A1 (en) * 2016-03-16 2017-09-21 Shire Human Genetic Therapies, Inc. Methods of purifying collagen 7
EP3676375A4 (en) 2017-08-31 2021-04-07 Green Cross Corporation METHOD OF PURIFYING A SULFATASE PROTEIN
WO2019126376A1 (en) * 2017-12-19 2019-06-27 Shire Human Genetic Therapies, Inc. Purified arylsulfatase a and compositons thereof
AU2019214519A1 (en) * 2018-02-02 2020-06-18 Aceragen, Inc. Methods for treating Farber disease
JP7465215B2 (ja) * 2018-04-12 2024-04-10 アムジェン インコーポレイテッド 安定なタンパク質組成物を製造する方法
CN112082832B (zh) * 2019-06-12 2022-03-29 华南理工大学 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法
CN110632052A (zh) * 2019-10-25 2019-12-31 山西师范大学 土壤芳基硫酸酯酶活性的荧光光谱检测法
CN112759643B (zh) * 2021-03-17 2023-05-30 华兰生物工程股份有限公司 一种血清白蛋白的脱脂方法
CN116693659A (zh) * 2023-07-11 2023-09-05 浙江大学 一种分离重组人血白蛋白的两步混合模式层析方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4315919A (en) 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
CA2041280A1 (en) * 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
ATE217799T1 (de) 1998-01-27 2002-06-15 Hemebiotech As Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
DK2270044T3 (en) 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
AU753468B2 (en) 1998-06-09 2002-10-17 Csl Behring Ag Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
AU774603B2 (en) 1999-07-27 2004-07-01 Zymenex A/S Production of rhPBGD and new therapeutic methods for treating patients with acute intermittent porphyria (AIP) and other porphyric diseases
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002040686A2 (en) 2000-11-15 2002-05-23 Genzyme Corporation Expression system for recombinant proteins
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
AU2002317701A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
EP1463512B1 (en) 2002-01-11 2014-05-28 biOasis Technologies Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
US7118675B2 (en) 2002-02-04 2006-10-10 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
EP1713904B1 (en) * 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
EP1740204B1 (en) 2004-04-01 2018-03-14 Chiesi Farmaceutici S.p.A. Medicinal use of alpha-mannosidase
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
PL2628746T3 (pl) 2006-04-04 2019-07-31 Chiesi Farmaceutici S.P.A. Sposób zatężania polipeptydu
CA2739352C (en) * 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
US8945895B2 (en) * 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
RU2626514C2 (ru) 2010-06-25 2017-07-28 Шир Хьюман Дженетик Терапис, Инк. Доставка к цнс лечебных агентов
EP3964230A1 (en) * 2010-06-25 2022-03-09 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of arylsulfatase a
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
WO2014110246A1 (en) 2013-01-09 2014-07-17 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase a

Also Published As

Publication number Publication date
JP2018171067A (ja) 2018-11-08
CN112126634A (zh) 2020-12-25
AU2020201079B2 (en) 2022-05-26
JP2020015750A (ja) 2020-01-30
HK1214622A1 (zh) 2016-07-29
EP2943568A1 (en) 2015-11-18
AU2022221475A1 (en) 2022-09-22
EA030551B1 (ru) 2018-08-31
EP2943568B1 (en) 2019-11-20
AU2020201079A1 (en) 2020-03-05
AU2014205441A1 (en) 2015-06-25
US20230235303A1 (en) 2023-07-27
JP6427502B2 (ja) 2018-11-21
MX2020003798A (es) 2020-08-03
CA2896979A1 (en) 2014-07-17
WO2014110246A1 (en) 2014-07-17
JP7407161B2 (ja) 2023-12-28
AU2014205441B2 (en) 2019-12-12
CN104903442A (zh) 2015-09-09
EA201590826A1 (ru) 2015-11-30
MX2015008875A (es) 2015-10-22
US11884945B2 (en) 2024-01-30
CA2896979C (en) 2023-05-02
US20150353904A1 (en) 2015-12-10
BR112015015948A2 (zh) 2017-08-15
ES2768261T3 (es) 2020-06-22
JP2024001160A (ja) 2024-01-09
JP2016504040A (ja) 2016-02-12
BR112015015948B1 (pt) 2022-05-17
US11407984B2 (en) 2022-08-09
JP2022023225A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
HRP20190197T1 (hr) Postupci pročišćavanja rna
IL240215A0 (en) Methods for the purification of messenger RNA
PL2803401T3 (pl) Oczyszczanie powietrza
HK1216429A1 (zh) 用於純化芳基硫酸酯酶 的方法
GB201401248D0 (en) Method of manufacture
HK1218014A1 (zh) 用以間接判定參考間距的方法
SG11201603028SA (en) Purification of proteins
SG11201505198WA (en) Protein purification methods
IL268868B (en) A new method for protein purification
PT2985275T (pt) Método de purificação do ácido beta-hidroxi-beta-metilbutírico
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
EP2948557A4 (en) PURIFICATION OF CADAVERINE
ZA201603797B (en) Novel purification processes
GB201305231D0 (en) Method of Manufacture
IL243937A (en) A process for the purification of compounds of diaminophenylazinium
GB201305514D0 (en) Method of water purification
HK1216419A1 (zh) 合成方法
HUE038331T2 (hu) Eljárás lecitin tisztítására
GB201314581D0 (en) Purification
SG10201701021XA (en) Method of synthesis
GB201311291D0 (en) Method of manufacture
GB201301262D0 (en) Method of manufacture
TWM475821U (en) Structure of mosquito-catch
TWM475524U (en) Structure of rivet-pulling